ARCT - Why Is Everyone Talking About Arcturus Therapeutics Stock?
Arcturus Therapeutics (NASDAQ: ARCT) stock has made some investors rich lately while causing headaches for others -- all depending on when they opened their positions. Those who bought shares last January and are still holding them are sitting on notional returns of more than 350%, while some who sold at the right time in the months that followed might have even booked returns of more than 1,100%. On the other hand, those who made their initial investments just a month ago have watched the stock tumble by a painful 50%.
Much of the stock's volatility stems from the company's flagship messenger RNA (mRNA) coronavirus vaccine candidate, ARCT-021. How is it that a potentially life-saving vaccine could cause such heartaches for investors?
Image Source: Getty Images.
For further details see:
Why Is Everyone Talking About Arcturus Therapeutics Stock?